Phase II study of trifluridine/tipiracil plus bevacizumab by RAS mutation status in patients with metastatic colorectal cancer refractory to standard therapies: JFMC51-1702-C7
针对对标准疗法无效的转移性结直肠癌患者,根据 RAS 突变状态评估三氟尿苷/替吡嘧啶联合贝伐单抗的 II 期研究:JFMC51-1702-C7
期刊:ESMO Open
影响因子:8.3
doi:10.1016/j.esmoop.2021.100093
Takahashi, T; Yamazaki, K; Oki, E; Shiozawa, M; Mitsugi, K; Makiyama, A; Nakamura, M; Ojima, H; Kagawa, Y; Matsuhashi, N; Okuda, H; Asayama, M; Yuasa, Y; Shimada, Y; Manaka, D; Watanabe, J; Oba, K; Yoshino, T; Yoshida, K; Maehara, Y